Bimzelx Disease Interactions

Bimekizumab can cause increased levels of liver enzymes and bilirubin. Treatment with bimekizumab should be avoided in patients with acute liver disease or cirrhosis as they may be at increased risk for severe hepatic injury.

Cases of Inflammatory Bowel Disease (IBD) have been reported in patients treated with bimekizumab. Treatment with bimekizumab should be avoided in patients with active IBD.

Patients with a history of suicidal ideation or behavior reported a higher rate of new onset of suicidal ideation when treated with bimekizumab. Patients with a history of severe depression are also susceptible to suicidal ideation or behavior when treated with bimekizumab.

Bimekizumab may increase the risk of infections, including tuberculosis (TB). Patients should be evaluated for any active infection before and during treatment with bimekizumab, and administration should be avoided if infection is detected. Evaluate patients for TB before treatment and avoid therapy in patients with active TB. Anti-TB therapy should be considered for patients with a history of latent or active TB.